CASE REPORT

Case Report: Successful use of fondaparinux in a case of heparin intolerance during pregnancy [version 1; peer review: 2 not approved]

Mohammed AlSheef1, Noura Shafi1, Bakhitah Aleid1, Abdul Rehman Zia Zaidi1,2, Ohoud AlArfaj3

1Department of Medicine, King Fahad Medical City, Riyadh, 11525, Saudi Arabia
2College of Medicine, Alfaisal University, Riyadh, 11525, Saudi Arabia
3Department of Clinical Pharmacy, King Fahad Medical City, Riyadh, 11525, Saudi Arabia

Abstract
Heparin is the anticoagulant of choice during pregnancy. However, in cases of intolerance or adverse effects, another anti-coagulant agent should be administered. Here, we describe a case of hypersensitivity skin reaction seen in a 37-year-old pregnant patient at 11 weeks of gestation who used low-molecular-weight heparin (LMWH). Fondaparinux was used as an alternative during her pregnancy with a successful outcome.

Keywords
Fondaparinux, Heparin Intolerance, Pregnancy, LMWH, Hypersensitivity, Anticoagulant

Open Peer Review

Reviewer Status

Invited Reviewers
1
2

version 1
28 Nov 2019

1. Saskia Middeldorp, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
2. Maha Othman, Queen’s University, Ontario, Canada

Any reports and responses or comments on the article can be found at the end of the article.
Introduction

Low-molecular-weight heparin (LMWH), such as enoxaparin, is the preferred anticoagulant for pregnant women due to its effectiveness, safety, and availability. However, if the pregnant patient experiences an allergy, side effect or intolerance, she should be switched to alternative anticoagulation medication. Unfortunately, in such circumstances, the other anti-coagulation options are limited due to teratogenicity, lack of literature support, or cross-reactivity with LMWH.

Fondaparinux, which is a synthetic polysaccharide inhibitor of activated factor X (FXa), has been reported to be a successful alternative anticoagulant in pregnant patients who develop heparin intolerance, such as hypersensitivity skin reaction, which is frequently seen in pregnant patients\(^1\). Although it crosses the placental barrier and results in low measurable anti-factor Xa activity in umbilical-cord blood\(^2\), it is considered relatively safe since there are no significant reported unfavorable side effects for the mother or child during pregnancy or the postpartum period.

Case report

A 37-year-old Saudi female homemaker (G6P4+1) with a history of hypothyroidism on thyroxin and a history of miscarriage and intrauterine fetal death (IUDF) presented to our thrombosis clinic. She explained to us that this is an important pregnancy for her and that she wished to deliver a healthy baby. Her gynecological history comprised of: preeclampsia during her first pregnancy, resulting in premature labor; fetal distress during her second pregnancy; a third pregnancy resulting in premature labor at 30 weeks; a fourth pregnancy resulting in IUDF at 25 weeks; fetal distress in the 31\(^{st}\) week of her fifth pregnancy in 2012; and a sixth pregnancy resulting in IUDF in 2015. Therefore, she was referred to our tertiary care hospital and to our clinic to prevent morbidity and mortality in the current pregnancy. She presented to our clinic in 2016, 11 weeks pregnant, and on physical examination, cardiac and respiratory exams were normal. Abdominal examination showed a gravid uterus. Thrombophilia work up including protein C, protein S, antithrombin III, factor V Leiden mutation, prothrombin gene mutation G20210A, and antiphospholipid antibodies were within normal limits (Table 1).

The patient was started on aspirin 81 mg once daily, and low-molecular-weight-heparin (LMWH) 4000 units via subcutaneous injection once daily. We explained to the patient the rationale for using heparin was to prevent placental microvascular thrombosis and therefore, prevent placental mediated complications such as preeclampsia and IUDF. This is an internationally recommended evidence-based practice.

Five days later, she developed a severe rash, as depicted in Figures 1A–1D. Hence, LMWH was discontinued, and she was asked to resume taking aspirin 81 mg once daily. She was

---

**Table 1. Laboratory values at the initial presentation and at follow-up visits.**

<table>
<thead>
<tr>
<th>Test</th>
<th>Value at initial presentation</th>
<th>Value at follow-up visits</th>
<th>Value at six weeks postpartum</th>
<th>Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td>White blood cells</td>
<td>(7.47 \times 10^9/L)</td>
<td>(7.28 \times 10^9/L)</td>
<td>(7.87 \times 10^9/L)</td>
<td>(4–11 \times 10^9/L)</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>(13.0) g/dL</td>
<td>(14) g/dL</td>
<td>(12.6) g/dL</td>
<td>(12–16) g/dL</td>
</tr>
<tr>
<td>Platelets</td>
<td>(300 \times 10^9/L)</td>
<td>(350 \times 10^9/L)</td>
<td>(332 \times 10^9/L)</td>
<td>(155 – 435 \times 10^9/L)</td>
</tr>
<tr>
<td>Creatinine</td>
<td>(41 \mu)mol/L</td>
<td>(54 \mu)mol/L</td>
<td>(58 \mu)mol/L</td>
<td>(44 – 80 \mu)mol/L</td>
</tr>
<tr>
<td>Aspartate aminotransferase</td>
<td>(18) U/L</td>
<td>(19) U/L</td>
<td>(21) U/L</td>
<td>(0 – 32) U/L</td>
</tr>
<tr>
<td>Alanine amino transferase</td>
<td>(8) U/L</td>
<td>(11) U/L</td>
<td>(12) U/L</td>
<td>(0 – 31) U/L</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>(124) U/L</td>
<td>(131) U/L</td>
<td>(121) U/L</td>
<td>(50–136) U/L</td>
</tr>
<tr>
<td>Activated partial thromboplastin time</td>
<td>(26.4) sec</td>
<td>(28) sec</td>
<td>(28) sec</td>
<td>(26–40) sec</td>
</tr>
<tr>
<td>International normalized ratio</td>
<td>0.9</td>
<td>1.1</td>
<td>1.0</td>
<td>0.9–1.2</td>
</tr>
</tbody>
</table>

**Thrombophilia Work-up**

<table>
<thead>
<tr>
<th>Test</th>
<th>Value at initial presentation</th>
<th>Value at follow-up visits</th>
<th>Value at six weeks postpartum</th>
<th>Reference range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anticardiolipin screen IgG</td>
<td>10.7</td>
<td>n/a</td>
<td>n/a</td>
<td>&lt;12.5</td>
</tr>
<tr>
<td>Anticardiolipin screen IgM</td>
<td>3.48</td>
<td>n/a</td>
<td>n/a</td>
<td>0–14.9</td>
</tr>
<tr>
<td>Anticardiolipin screen IgA</td>
<td>&lt;8.0</td>
<td>n/a</td>
<td>n/a</td>
<td>&lt;12</td>
</tr>
<tr>
<td>B2 - Glycoprotein I IgG</td>
<td>2.3 U/mL</td>
<td>n/a</td>
<td>n/a</td>
<td>0–20 U/mL</td>
</tr>
<tr>
<td>B2 - Glycoprotein I IgM</td>
<td>5.6 U/mL</td>
<td>n/a</td>
<td>n/a</td>
<td>0–20 U/mL</td>
</tr>
<tr>
<td>B2-Glycoprotein I IgA</td>
<td>19.1 U/mL</td>
<td>n/a</td>
<td>n/a</td>
<td>0–20 U/mL</td>
</tr>
<tr>
<td>Protein S</td>
<td>78.4%</td>
<td>n/a</td>
<td>n/a</td>
<td>50–123%</td>
</tr>
<tr>
<td>Protein C</td>
<td>94.2%</td>
<td>n/a</td>
<td>n/a</td>
<td>70–140%</td>
</tr>
<tr>
<td>Antithrombin III</td>
<td>101.2%</td>
<td>n/a</td>
<td>n/a</td>
<td>70–125%</td>
</tr>
<tr>
<td>Lupus anticoagulation - La1</td>
<td>35.4 sec</td>
<td>n/a</td>
<td>n/a</td>
<td>31–44 sec</td>
</tr>
<tr>
<td>Factor V Leiden (APCR)</td>
<td>1.2</td>
<td>n/a</td>
<td>n/a</td>
<td>0.69–2.0</td>
</tr>
<tr>
<td>Prothrombin gene mutation G20210A</td>
<td>Negative</td>
<td>n/a</td>
<td>n/a</td>
<td>Negative</td>
</tr>
</tbody>
</table>
found to be allergic to LMWH (such as enoxaparin and tinzaparin), resulting in symptoms such as swelling, itching, and erythema, which slowly resolved one week after discontinuation of heparin. One month later, on her scheduled follow-up appointment with us, she no longer had any skin rash or any other hypersensitivity reaction symptoms. We suggested fondaparinux 2.5 mg delivered subcutaneously once daily. We explained to the patient that fondaparinux was an alternative anticoagulant for patients intolerant to heparin, with no reported hypersensitivity reactions or adverse effects on the fetus. She agreed, and hence we discontinued aspirin and started her on fondaparinux. We monitored her health through monthly follow-up clinic visits with regular laboratory tests and ultrasounds in the maternal fetal medicine and thrombosis clinics (Table 1). The ultrasounds had no significant findings, with a single viable fetus and normal growth. She was well with no allergic symptoms or discomfort, and kept taking fondaparinux for five months until her planned induction of labor at 38 weeks gestation with cessation of fondaparinux for 24 hours. She delivered a normal healthy baby and we followed up regularly with the patient for six weeks postpartum (Table 1).

Discussion

Heparin has always been the anticoagulant of choice to prevent and treat a thrombotic event during pregnancy. However, its use is limited when adverse reactions such as skin rash (type I hypersensitivity reaction) or heparin-induced thrombocytopenia occurs. Hence, in the setting of heparin intolerance with a high risk of thrombosis, alternative choices for anticoagulation becomes limited.

Current evidence shows that fondaparinux is a safe and effective alternative option in the circumstances, such as seen in our case. For instance, a retrospective study comparing the efficacy of fondaparinux to enoxaparin in terms of pregnancy success rate, gestational age, birth weight, and major bleeding complications concluded that both anticoagulants have comparable results. In addition, a prospective study evaluating the effect of a prophylactic dose of fondaparinux in pregnant women with a history of venous thromboembolism reported 100% uneventful pregnancies without thromboembolic complications. However, there is limited experience in the use of fondaparinux in pregnancy, but it has been used in patients with heparin intolerance with no reported adverse effects to the fetus or the mother.

In concordance with the literature, our patient had an uneventful pregnancy without developing an adverse reaction to fondaparinux. With regards to the long-term safety of fondaparinux, several studies in the literature reported no significant difference in safety profile compared to enoxaparin over a period of therapy ranging between a few weeks to eight months.

On the other hand, umbilical blood sampling showed a detectable level of anti-factor Xa, indicating the passage of fondaparinux to fetal circulation. However, the accumulative
level is measured and found to be subtherapeutic, and no study reported any complications during pregnancy or post-partum.

Conclusion
In conclusion, our case demonstrates that fondaparinux is a safe and effective anticoagulant option in the presence of heparin intolerance.

Data availability
All data underlying the results are available as part of the article and no additional source data are required.

Consent
Written informed consent for publication of their clinical details and clinical images was obtained from the patient.

References

3. Royal College of obstetricians and gynaecologists reducing the risk of venous thromboembolism during pregnancy, April 2015. Reference Source
The authors report successful use of fondaparinux in managing heparin intolerance during pregnancy in a 37 y old pregnant lady at her 11 w of gestation.

Hypersensitivity reactions to heparin in pregnancy is not a new issue and is reported in ~ 20% of patients. The successful use of fondaparinux is not new either. So I am not sure if this is still worth reporting. Also, I am not sure I would agree with authors that the experience fondaparinux use in pregnancy is still limited.

The most interesting part of this case in my view is to identify the pathology underlying this poor obstetric history (repeatedly complicated pregnancies, labours and multiple IUFDs). The thrombophilia screen is all normal. The authors included APS work up, however these antibodies were only measured once; against the standard diagnostic guidelines. The possibility of APS still exists in this case and requires further investigation.

I encourage the authors to shift focus towards diagnosis of the pathology for this poor obstetric history; perform further investigations and rewrite the case report. This will provide some novelty and help educate the scientific community in similar cases.

Is the background of the case's history and progression described in sufficient detail? Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes? Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?
Partly

Is the case presented with sufficient detail to be useful for other practitioners?
Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Haemostasis, coagulopathies in placenta mediated complications, Women's Health

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

Reviewer Report 03 December 2019
https://doi.org/10.5256/f1000research.23336.r57377

© 2019 Middeldorp S et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Saskia Middeldorp
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Hanke Wiegers
Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

This case report on fondaprinux in a pregnant woman with LMWH allergy does not lead to new insights into the knowledge of heparin allergy or fondaparinux.

Important references about the occurrence of type IV (?) allergy to LMWH and how to deal with this, have not been referenced (for instance, Schindewolf, Lancet) It is therefore surprising that the authors immediately chose to use fondaparinux and not other types of LMWH.

The authors imply causal inference between use of anticoagulants and the successful pregnancy outcome, which cannot be made on a single case.

Reference to guidelines regarding the use of LMWH to improve outcome in IUFD is missing.

Is the background of the case's history and progression described in sufficient detail?
No

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?
Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment? No

Is the case presented with sufficient detail to be useful for other practitioners? No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: VTE

We confirm that we have read this submission and believe that we have an appropriate level of expertise to state that we do not consider it to be of an acceptable scientific standard, for reasons outlined above.

The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com